New dPCR core facility in ShareLab

Published: 17 April 2024

Text: ShareLab

Photo: Sigurd Reistad Klæva

On a mission to establish dPCR as a mainstream technology in the Norwegian biotech industry, QIAGEN has selected ShareLab as the base for a new “industrial core facility”.

Here anyone wanting to test or use dPCR can get access to QIAGEN’s state-of-the-art QIAcuty instruments. Scientists from companies and institutes can come to ShareLab to receive training and demos, run tests, or run both small and large projects on these. In addition to the instruments, they will also find kits and materials here, plus the expertise they need to set up their experiments and procedures and to evaluate and improve their results.

“This is a strategic partnership”, says Christine Vimo, Senior Account Manager at QIAGEN.

“ShareLab’s attractive location and facilities, their sharing-economy concept, and their exciting community of cutting-edge biotech startups, makes the perfect environment for us to establish our dPCR core facility. With this, QIAGEN will be able to make dPCR capabilities and tools available to many more Norwegian companies and scientists than we previously thought possible. We are very excited to be here!”

Christine Vimo, Senior Account Manager at QIAGEN (middle) together with ShareLab's Marius Øgaard and Samrawit M. Gebretensaie.

QIAGEN’s innovative dPCR solutions provide a whole new level of sensitivity and precision in nucleic acid detection and quantification.

“At ShareLab we are constantly working to improve and expand the equipment in our lab, so that we can always offer the best tools to our members. This new partnership goes far beyond that!” says Marius Øgaard, Partner at ShareLab.

“By establishing this new core facility together, QIAGEN and ShareLab are reaching out with an attractive new offering to anyone in Norway who is interested in upgrading from qPCR/PCR to dPCR. Even if it is a relatively simple solution to implement, we believe this can be a stepping stone project for the whole industry.”